SynthesisCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2006
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Synthesis in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Pooled it
- Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011Trial
- Speech in Line: A Catholic Ethical Approach in Prioritizing Children with Speech Delay or Elderly Stroke Survivors Amidst the Scarcity of Speech-Language Pathologists in the Philippines.Journal of religion and health · 2026Article
- 'Bone Health-Across a Woman's Lifespan'.Clinical endocrinology · 2025Review
- sLZIP functions as a key modulator of bone remodeling by regulating the crosstalk between osteoblasts and osteoclasts.Experimental & molecular medicine · 2025Article
- Unraveling the relationship between serum parathyroid hormone levels and trabecular bone score: a cross-sectional study.Scientific reports · 2024Article
- Topical application of the plant extract SDTL-E in ovariectomized rats: A potential new approach for treating osteoporosis.Frontiers in medicine · 2022Article
- An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAPBone research · 2021Article
- Present and future scope of recombinant parathyroid hormone therapy in orthopaedics.Journal of clinical orthopaedics and trauma · 2021Review
- Scope and Limits of Teriparatide Use in Delayed and Nonunions: A Case Series.Clinics and practice · 2021Article
- The Effect of Thyroid Hormone, Prostaglandin E2, and Calcium Gluconate on Orthodontic Tooth Movement and Root Resorption in Rats.Journal of dentistry (Shiraz, Iran) · 2015Article
- Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Observational
- Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Nutrition research reviews · 2014Review
- The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy.Archives of medical science : AMS · 2013Article
- Skin anti-aging strategies.Dermato-endocrinology · 2012Article
- Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm.Cellular and molecular life sciences : CMLS · 2011Review
- Usability evaluation of a clinical decision support tool for osteoporosis disease management.Implementation science : IS · 2010Article
- Prevention of osteoporosis-related fractures among postmenopausal women and older men.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Review
- Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Management of osteoporosis in men: an update and case example.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2007Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundHuman parathyroid hormone (hPTH)(1-34) was approved in 2004 for the treatment of severe osteoporosis. Members of the Osteoporosis Canada clinical guidelines committee conducted a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of hPTH for fracture prevention in postmenopausal women and men with osteoporosis.
methodsWe searched MEDLINE, EMBASE, HTA, Current Contents and the Cochrane Controlled Trials Registry for published data from 1966 to February 2005. A systematic literature search for RCTs was conducted using the Cochrane Collaborative approach. We identified 12 trials that randomly assigned patients either to hPTH or placebo or to hPTH or an active comparator and were at least 1 year in duration. Outcomes included change in bone mineral density (BMD), fractures, back pain and adverse events. Two independent reviewers abstracted data on study characteristics and outcomes.
resultshPTH(1-34) significantly increases lumbar spine BMD, with smaller increases at the femoral neck and total hip. hPTH(1-84) significantly increases lumbar spine BMD. The data show a significant reduction in both vertebral and nonvertebral fractures with hPTH(1-34) in postmenopausal women with previous vertebral fractures. There were no data on fractures comparing the approved dose of hPTH(1-34) with active comparators.
interpretationThere is Level I evidence that hPTH(1-34) significantly increases BMD at all skeletal sites except the radius and significantly reduces the risk of new vertebral and nonvertebral fractures in postmenopausal women with prior fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.